ArticleJournal of translational medicine2026
Inhibition of glutamine metabolism blocks tumor growth and sensitizes ccRCC to immune checkpoint blockade.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026Review
- 70 Years of DON and Beyond: Glutaminase Inhibition as a Synergistic Strategy in Cancer Combination Therapy.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMetabolic reprogramming of glutamine plays a pivotal role in the progression of clear cell renal cell carcinoma (ccRCC). Although inhibition of glutamine metabolism has been shown to suppress ccRCC progression, its effect on tumor immune evasion remains poorly understood.
methodsBioinformatic analysis and glutamine deprivation assays were performed to investigate the association between glutamine metabolism and clinical outcomes in ccRCC, as well as its effect on tumor cell proliferation. Western blot, flow cytometry, MTT, ELISA, RNA-Seq, immunohistochemistry, and multiplex immunofluorescence were used to evaluate the antitumor effects of the glutamine antagonist DON/DRP-104 and the glutaminase inhibitor CB-839 both in vitro and in vivo, along with their impacts on PD-L1 expression in tumor cells and CD8⁺T cell function. RNA-Seq, Western blot, flow cytometry, and immunofluorescence were further employed to explore the mechanisms by which DON/DRP-104 and CB-839 regulate PD-L1 expression. Finally, in vivo experiments were performed to evaluate the antitumor effects of DRP-104 or CB-839 in combination with an anti-PD-L1 antibody in renal cancer.
resultsWe demonstrate that pharmacological inhibition of glutamine metabolism with DON/DRP-104 or CB-839 effectively suppressed tumor cell viability in vitro by inhibiting proliferation and inducing apoptosis, and delayed tumor progression in vivo. However, this metabolic inhibition paradoxically impaired CD8+T cell function. Further investigation revealed that inhibition of glutamine metabolism upregulated PD-L1 expression on tumor cells via a reactive oxygen species (ROS)-dependent EGFR/ERK1/2/c-Jun signaling pathway. Consequently, combining DRP-104 or CB-839 with anti-PD-L1 therapy enhanced the efficacy of immune checkpoint inhibitors (ICIs) in mouse models.
conclusionWhile inhibition of glutamine metabolism blocks renal cancer growth, it concurrently impairs CD8⁺T cell function by upregulating PD-L1 expression on tumor cells via a ROS-dependent EGFR/ERK1/2/c-Jun pathway. Combining DRP-104 or CB-839 with ICIs restores CD8⁺T cell function and improves antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.